C Diff Treatment

“.@bhmullish also summarizes available approaches for preventing C. difficile infection including probiotics, anti-CDI antibiotics and ribaxamase. @esnm_eu #GMFHCoverage”

Are you having ongoing digestive problems like diarrhea and cramping pain? If you are wondering if a recent C. diff. infection can cause problems like this,  then you're in the right place.  In this article we look at this topic.  The impact of c. diff. in causing long-term chronic digestive issues.  This is another form of post-infectious IBS.  Research Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296708/ Florastor probiotic (Affiliate link): https://geni.us/kknw0f (Amazon) Pure GG (Affiliate link): https://geni.us/z5faaBV (Amazon) Saccharomyces boulardi (Affilate link): https://geni.us/FQC13DA (Amazon) C. diff. also known as clostridium difficile can cause massive digestive tract disturbances like diarrhea, dehydration, cramping, and pain.  It can even lead to systemic symptoms like fever, body, aches, and chills in a similar way as a cold or flu.  The clostridium difficile bacteria can actually be part of our normal digestive flora like the  "good commensal bacteria."  When it is allowed to grow unchecked by the other good bacteria in your microbiome, it can get out of control in a sense.  This bacteria typically lives in harmony with the other bacteria in our microbiome.  Not everybody has it in their digestive tract but a lot of people do often it is in relative balance with the other microbes.  It even supports the digestive cells and contributes to our overall digestive health.  This is what happens when it's in normal or small amounts in our digestive tract.  Typically the problems from this microbe arise when we take antibiotics.   The reason for taking the antibiotic could be any really.  Those antibiotics start to reduce the number of the good bacteria.  These are in competition with the clostridium difficile or c. diff. bacteria constantly.  When some of those get wiped out, the c. diff. has the ability to emerge, grow, and expand its territory.  They will expand outside of the small territory that was supportive for our digestive tract.  Once this happens there are too many of them to keep in check leading to many problems.  This is when we start to have major digestive symptoms.  So the antibiotics reduce your good bacteria.  The c. diff. does not get weakened by the antibiotics depending on which one it is.  It is just not sensitive to many of them.  Meanwhile the good bacteria are dying off.  As they are trying to come back and recover, the c diff is expanding and expanding. While they're expanding, they're also producing a toxin.  That toxin can cause your immune system to respond and cause a lot of internal inflammation in the digestive tract.  Also what happens is you get increased water flooding into that digestive tract to flush out that toxin.  When that happens that's when you get the uncontrolled diarrhea.  Once it's treated with either vancomycin or metronidazole, that c diff will recede.  With this you will become less symptomatic.  However this microbe is fairly crafty and can easily form spores.  Those spores are basically like a capsule that protects the internal DNA and the overall structure of the bacteria.  It doesn't allow the antibiotics to affect them.  When in the spore formation the bacteria are basically in a hibernated state.  Once you are done taking that antibiotic and it flushes through your system, that c diff can start to re-emerge again.  Depending on the overall quantities that are there, and what's going on with your good bacteria, they can start gaining territory again.  With this they will produce more of this toxin.  Once that shifts to a point where the toxin is stimulating your immune system, it will cause increased fluid to come in.  Depending on how much of that toxin the c diff producing, determines if you have diarrhea again. So does C. diff. cause long-term problems? Yes, it can if it's not eradicated with that first or second round or antibiotics or goes unnoticed.  You may have less severe symptoms than initially but they can still be there.  There are some studies looking  at the rates of digestive problems following a C. diff. infection.  They found that there's much higher rates of digestive problems in people whom previously had a C. diff. infection. This lasted for up to 12 months following that original infection.  In fact, the study participants were eight times more likely to be readmitted to the hospital for another digestive problem.  That persisted for up to 12 months.  There's also more general digestive issues like IBS symptoms that can persist for even longer 24 months or possibly even a longer time period.  This is just another form of post-infectious IBS.  When you have this there are lingering amounts of the microbe there and either the immune system, the antibiotic, or the local environment has not been able to keep it in check.  It's the persistence of that microbe and the overall long-term damage that happens from that microbe that creates this increased risk for ongoing problems.

This article focuses on the factors that predict long-term complications of C. difficile infection and what can be done in clinical practice to minimize them.

Some excellent webinars and videos available from the members of @WelshAbx in support of #WAAW . #IVOST #cdiff #KeepAntibioticsWorking @CV_Pharmacy https://t.co/KwO3Ec0E1O— Ruth (@ruth_abx) November 18, 2022

Nature Biotechnology - Improving combination drug trials using ‘definitive screening designs’

Clostridioides difficile is endemic in the intestinal tract of healthy people. However, it is responsible for many healthcare-associated infections, such as nosocomial diarrhea following antibiotic treatment. Importantly, there have been cases of unsuccessful treatment and relapse related to …

Objective To appraise the evidence that pathophysiological mechanisms and individualised treatment directed at those mechanisms provide an alternative approach to the treatment of patients with irritable bowel syndrome (IBS). Design A PubMED-based literature review of mechanisms and treatment of IBS was conducted independently by the two authors, and any differences of perspective or interpretation of the literature were resolved following discussion. Results The availability of several noninvasive clinical tests can appraise the mechanisms responsible for symptom generation in IBS, including rectal evacuation disorders, abnormal transit, visceral hypersensitivity or hypervigilance, bile acid diarrhoea, sugar intolerances, barrier dysfunction, the microbiome, immune activation and chemicals released by the latter mechanism. The basic molecular mechanisms contributing to these pathophysiologies are increasingly recognised, offering opportunities to intervene with medications directed specifically to food components, receptors and potentially the microbiome. Although the evidence supporting interventions for each mechanism is not at the same level of proof, the current state-of-the-art provides the opportunity to advance the practice from treatment based on symptoms to individualisation of treatment guided by pathophysiology and clinically identified biomarkers. Conclusion These advances augur well for the implementation of evidence-based individualised treatment for patients with IBS based on actionable biomarkers or psychological disturbances. All data relevant to the study are included in the article.

Acurx Pharmaceuticals stock is again in play. And for good reasons. In October, ACXP released additional positive clinical data evaluating ibezapolstat, its orally administered antibiotic being... | November 15, 2022

Erratum for Hogan et al., "Clinical Outcomes of Treated and Untreated C. difficile PCR-Positive/Toxin-Negative Adult Hospitalized Patients: a Quasi-Experimental Noninferiority Study"

As CDI is associated with excess mortality, LOS, and cost in children hospitalized for CF, a healthy level of suspicion for CDI may be needed in patients with CF in the appropriate clinical context. Efforts to prevent, diagnose, and treat CDI may improve hospital outcomes among children with CF. Thi …

This study delineated a comprehensive landscape of the advancement in FMT field. Although in its infancy, FMT is a burgeoning option for the treatment of a variety of diseases associated with gut dysbiosis. To improve the efficacy and reduce adverse events, future studies are warranted to optimize t …

Clostridioides difficile infection (CDI) is the leading cause of antibiotic-associated diarrhea and an important nosocomial infection with different severity degrees. Disruption of the gut microbiota by broad-spectrum antibiotics creates a proper environment for C. difficile colonizati …

Background:Clostridioides difficile (C. difficile) infection (CDI) is strongly associated with inflammation and has the potential to cause recurrent infections. Pre-clinical data suggest that melatonin has beneficial effects in the gastrointestinal tract due to its anti-inflamma …

Bezlotoxumab administration during the standard of care antibiotic therapy is effective and safe in reducing the rate of rCDI. Despite its high cost, evidence suggests considering bezlotoxumab in patients with a primary CDI episode. Further studies are needed to assess the benefit in specific subgro …

Post colonic resection, IBD-CDI patients have worse outcomes than IBD patients without CDI. These patients represent a particularly vulnerable cohort who require close monitoring for the development of postoperative complications.

Future perspectives Chair: Qasim Aziz, London, United Kingdom Clinical view on C. diff management in the future, Ben Mullish, United Kingdom Future developments in microbiome research, Ken Blount, United States Followed by Q&A with all chairs and speakers

As part of #CdiffAwarenessMonth, we are #SeresProud to sponsor @IDSAFoundation webinar “The Burden of C. diff” at 1pm ET November 8. Register now to hear from the #Cdiff community, including physicians, patient advocates and survivors: https://t.co/GaoRRpaKIB pic.twitter.com/ARnbXgUF6l— Seres Therapeutics (@SeresTX) November 7, 2022

PURPOSE OF THE STUDY To identify risk factors associated with developing Clostridium difficile infection (CDI) in adolescent idiopathic scoliosis patients after surgery and to describe the clinical presentation of CDI in these patients. Clostridium difficile colitis is reportedly increasing in hospi …

Recurrent #CDI occurs in 20% to 30% of patients, with increasing rates of recurrence with each subsequent episode. #FridayMicrobiomeVibes #Cdiff pic.twitter.com/jqYfsdkvN9— Microbiome Science (@MbiomeScience) November 4, 2022

Clostridioides difficile remains a major cause of morbidity and mortality in the intensive care unit, and therefore, C difficile guidelines are frequently being updated. Currently, fidaxomicin is the suggested treatment of initial and recurrent infection. Oral vancomycin is an acceptable alternative …

Clostridioides difficile infection is difficult to diagnose, prevent, and treat. In addition, minimizing the risk for recurrent infection remains a significant ...

ZINPLAVA (#bezlotoxumab) InjectionIndications & Dosing#MedTwitter #IDTwitter #internalmedicine #urgentcare #usmle #PharmaTwitter @Merck #Zinplava #cdiff #biotech pic.twitter.com/pyL2Y83O8C— ApoThera - Clinical Decision Support - Mobile App (@ApoThera) November 2, 2022

Researchers assessed the effects of adjunctive eravacycline therapy in patients with recurrent, severe, or fulminant Clostridioides difficile infection.

Acurx Pharmaceuticals (NasdaqCM: ACXP) provided more good news related to its ongoing clinical trial evaluating ibezapolstat, its orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. Two presentations, one a scientific oral presentation and the other a poster, highlighted new information about its lead antibiotic ibezapolstat and its selectivity against Gram-positive gut […]

Here's a clip from our past Masterclass on Bezlotoxumab for C. difficile Infections by Sarah Kessler, PharmD, BCPS, BCGP.🖱️Click the link in bio to view the whole course and download the handout.#pacu #Bezlotoxumab #cdiff #masterclass #pharmacistlife #pharmacotherapy pic.twitter.com/OuNsnc9WE5— Pharmacy & Acute Care University (@PharmacyAcute) October 31, 2022

Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).

Researchers evaluated the incidence of Clostridioides difficile infection among pediatric patients hospitalized between 2013 and 2019.